My PCR
Create Account
Logo PCR

15 May 2024

TAVI

LANDMARK RCT - Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial

Sponsored by Meril

Anchorperson: A. Baumbach
Spokeperson: P. Serruys
SHOW MORE

Summary

This session provides an overview of the early outcomes of the LANDMARK trial, a randomized non-inferiority trial comparing TAVI devices. It examines baseline characteristics, the significance of intermediate sizes according to MSCT recommendations, real-world representative cases from the LANDMARK RCT, insights from quantitative aortography and echocardiography at pre-discharge and 30 days, the treatment of conduction disturbances, and the added value of Myval THV series to daily practice.

Learning Objectives

  • To learn more about the first randomised trial that will report long-term (10 years) head-to-head outcomes to prove the non-inferiority of newer generation balloon-expandable Myval transcatheter heart valve series with commercially available contemporary TAVI devices (Sapien and Evolut transcatheter heart valve series)
  • To check 30-day composite endpoint based on the Valve Academic Research Consortium-3 consensus
Related Content
Treating severe restenosis of a 20-mm balloon-expanding valve after a transapical approach with a risk of coronary obstruction Unusual and high-stakes interventions Calcium modification and atherectomy
Recommended for you
What’s new in the 2025 guidance on valvular heart disease - ESC Congress 2025 Key updates in valvular heart disease management: insights from the 2025 ESC/EACTS Guidelines TAVI for pure aortic regurgitation - LIVE case